RXDX   $199.92  0.10% Market Closed

Prometheus Biosciences Inc
Total Cash
totalCashPerShare
EBITDA
Total Debt
quickRatio
currentRatio
Total Revenue
debtToEquity
Revenue/Share
ROA
ROE
grossProfits -106.04M
freeCashflow
operatingCashflow
earningsGrowth
revenueGrowth
grossMargins
ebitdaMargins
operatingMargins
profitMargins
enterpriseValue
forwardPE
floatShares
sharesOutstanding
sharesShort
sharesShortPriorMonth
dateShortInterest
sharesPercentSharesOut
heldPercentInsiders
heldPercentInstitutions
Short Ratio help_outline
shortPercentOfFloat
impliedSharesOutstanding
bookValue
Price To Book help_outline
earningsQuarterlyGrowth
netIncomeToCommon
trailingEps
forwardEps
enterpriseToEbitda
lastDividendValue
lastDividendDate
currentQuarterEstimate -0.94 2Q 2023
institutionsCount
lastUpdated Aug. 18, 2023, 3:31 p.m.